TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03491332

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: conventional circuit
Description: The patient enters the operating room without any pretreatment and attaches a standard patient monitoring device. Anesthesia was performed by intravenous anesthesia. After induction of anesthesia, alveolar recruitment is performed in supine position in all groups with 30 cmH2O for 5 seconds. Mechanical ventilator was set with tidal volume of 8 ml / kg, the inspiratory/ expiratory ratio of 1: 2 and respiratory rate was adjusted for targeting EtCO2 around 35mmHg. Keep the fresh air flow of the ventilator at 3 L / min and set the temperature to 37 ° C for the heating circuits of group H and group SH. An arterial cannulation and subclavian jugular vein catheter is inserted.~The circuits were applied to each group as follows; conventional circuit or group C, conventional humidification circuit for group H and new humidification heat circuit for group SH, respectively. All other conditions were same among three groups.
Study: NCT01812447

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Management
Description: Stable management is based on the ACP/ACCP/ATS/ERS Guidelines for Management of Stable COPD. Medical management will include management of COPD medications, oxygen use, and pulmonary rehabilitation.
Study: NCT03491332

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional humidification circuit
Description: The patient enters the operating room without any pretreatment and attaches a standard patient monitoring device. Anesthesia was performed by intravenous anesthesia. After induction of anesthesia, alveolar recruitment is performed in supine position in all groups with 30 cmH2O for 5 seconds. Mechanical ventilator was set with tidal volume of 8 ml / kg, the inspiratory/ expiratory ratio of 1: 2 and respiratory rate was adjusted for targeting EtCO2 around 35mmHg. Keep the fresh air flow of the ventilator at 3 L / min and set the temperature to 37 ° C for the heating circuits of group H and group SH. An arterial cannulation and subclavian jugular vein catheter is inserted.~The circuits were applied to each group as follows; conventional circuit or group C, conventional humidification circuit for group H and new humidification heat circuit for group SH, respectively. All other conditions were same among three groups.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: new humidifaction heat circuit
Description: The patient enters the operating room without any pretreatment and attaches a standard patient monitoring device. Anesthesia was performed by intravenous anesthesia. After induction of anesthesia, alveolar recruitment is performed in supine position in all groups with 30 cmH2O for 5 seconds. Mechanical ventilator was set with tidal volume of 8 ml / kg, the inspiratory/ expiratory ratio of 1: 2 and respiratory rate was adjusted for targeting EtCO2 around 35mmHg. Keep the fresh air flow of the ventilator at 3 L / min and set the temperature to 37 ° C for the heating circuits of group H and group SH. An arterial cannulation and subclavian jugular vein catheter is inserted.~The circuits were applied to each group as follows; conventional circuit or group C, conventional humidification circuit for group H and new humidification heat circuit for group SH, respectively. All other conditions were same among three groups.
Study: NCT03725410

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Venus Fiore Study Treatment
Description: Study treatment consists of delivering radiofrequency (RF) and pulsed electromagnetic fields (PEMF) internally to the vagina (50 - 70% for up to 15 minutes), externally to the labia (10 - 35% for up to 10 minutes) and externally to the mons pubis (10 - 35% for up to 15 minutes).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Venus Fiore Sham Treatment
Description: Sham treatment consists of delivering radiofrequency (RF) and pulsed electromagnetic fields (PEMF) internally to the vagina (1% for up to 15 minutes), externally to the labia (1% for up to 10 minutes) and externally to the mons pubis (1% for up to 15 minutes).
Study: NCT02072473

Intervention type: PROCEDURE
Intervention: Coronary sinus / left-sided slow pathway ablation
Description: Patients with unsuccessful right-sided slow pathway ablation attempt will undergo a stepwise:~1. coronary sinus slow pathway ablation, which, if unsuccessful, will be followed by~2. left-sided slow pathway ablation, using trans-septal approach.
Study: NCT00880815

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo ASCT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin
Description: Given IV
Study: NCT04587778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: intravenous infusion
Study: NCT00880815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV and PO
Study: NCT02479802

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Albumin
Description: 27 plasma exchange procedures using Albumin 5% (estimated 3000 mL per plasma exchange) as replacement solution:~* three weeks of intensive treatment with two plasma exchanges per week~* twenty-one weeks of maintenance treatment with one weekly plasma exchange
Study: NCT01888458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micafungin
Description: All patients meeting selection criteria will receive micafungin IV. Prophylaxis will start within 48 hours of the beginning of the transplant-related conditioning regimen until 5 days after recovery from neutropenia (ANC ≥ 500/µl), or occurrence of an IFI, or up to 42 days, or withdrawal for any reason (e.g. patient's or investigator's decision, development of intolerance, death), whichever come first
Study: NCT03757988

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention- PACE-Life
Description: Subjects will be provided with a Fitbit wristband and instructed how to use it. During the first group session, subjects will be taught how to use their heart rate (on the Fitbit) to determine how fast subjects should walk (to achieve the appropriate exercise dosage). Information on proper care, usage, and how to determine the appropriate heart rate from the watch, which will be used to guide the intensity of the walk will be provided to subjects and reviewed at each group session. For all clinic based group sessions, subjects will arrive at the STEP clinic to meet the entire group and leaders and be reminded of the HR that corresponds with the intensity of that group session. Next, the group will go outside and walk for 30 minutes.
Study: NCT02617810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922
Description: Participants will receive JNJ-42847922 20 milligram (mg) tablet orally once daily from Day 1 to Day 9.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Participants will receive midazolam 4 milligram (mg) syrup orally once on Day 1 during treatment A and on Day 7 during treatment B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Participants will receive warfarin 25 milligram (mg) tablet orally once on Day 3 during treatment A and on Day 9 during treatment B.
Study: NCT02456350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: On days -5 through -3, Fludarabine 30mg/m2 IV will be infused over 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: On days -5 through -3, Cyclophosphamide 300mg/m2 IV will be infused over 60 minutes followed by fludarabine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD19-CAR transduced T cells
Description: Modified cells will be infused IV over 30 minutes (2-4 days after the last dose of fludarabine).
Study: NCT01418001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib 400 mg QD - Gemcitabine and Docetaxel in Combination
Description: Patients who meet the eligibility criteria above will be treated with the combination therapy of Gemcitabine, Docetaxel, and Pazopanib for two cycles and subsequently re-evaluated for treatment effect. If no progression of the tumor is seen, patients will continue with two more cycles of treatment (total four cycles). Those patients who have progression of disease will proceed directly to surgical resection.~Following completion of neoadjuvant treatment, all patients will have definitive surgical resection. Following recovery from surgery, patients will proceed with adjuvant radiation therapy. Patients will then be followed for 2 years or until January 1st 2015, whichever comes first .
Study: NCT01316250

Intervention type: DRUG
Group type: OTHER
Intervention: Nilotinib
Description: Nilotinib 300 mg orally twice per day for 12 months followed by imatinib mesylate at a dose of 400 mg orally daily
Study: NCT00769145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: 0.5mg subconjunctival dose of ranibizumab 3 days prior to corneal transplantation and at the time of corneal transplantation (total 2 injections).
Study: NCT01627587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK221149 750 mg
Description: Treatment A: 750 mg GSK221149 single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: Treatment B: 400 mg of Ketoconazole single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK221149 100 mg
Description: Treatment C: 100mg of GSK221149 single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK221149 750 mg Fasted
Description: Treatment D: 750 mg of GSK221149 administered fasted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK221149 750 mg + Food
Description: Treatment E: 750 mg of GSK221149 administered with a high fat meal
Study: NCT01237366

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resilient Affective Processing Therapy (RAPT)
Description: Participants will be asked to complete 7 intervention sessions which include: 1) expressive writing exercises that focus on exploring thoughts and feelings surrounding a difficult life experience; and 2) stress management skills training to assist participants with managing any acute increases in distress that arise following the writing experience.
Study: NCT03685461

Intervention type: OTHER
Group type: OTHER
Intervention: Electrocochleography
Description: Electrocochleography is a noninvasive method of monitoring for acoustic evoked electrophysiologic responses from the cochlea. A speaker in the external auditory canal presents a tone burst stimulus and a nearby electrode, in this case from the apical electrode of the cochlear implant, records changes in the electrical activity within the cochlea. Different functional elements within the cochlea have signature electrophysiologic responses that can be isolated and studied individually. Through the use of intracochlear electrocochleography during cochlear implant electrode insertion valuable insight can be gained about structural or physiological changes that may be occurring.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrocochleography
Description: Electrocochleography is a noninvasive method of monitoring for acoustic evoked electrophysiologic responses from the cochlea. A speaker in the external auditory canal presents a tone burst stimulus and a nearby electrode, in this case from the apical electrode of the cochlear implant, records changes in the electrical activity within the cochlea. Different functional elements within the cochlea have signature electrophysiologic responses that can be isolated and studied individually. Through the use of intracochlear electrocochleography during cochlear implant electrode insertion valuable insight can be gained about structural or physiological changes that may be occurring.
Study: NCT03198494

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acoustic 1Hz Stimulation
Description: 1Hz acoustic pulses delivered during sleep via headphones

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Background Noise
Description: Background Noise used as a control
Study: NCT02950233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMDA active
Description: NMDA active group will involve ketamine (0.5 mg/kg IV bolus pre-incision and 0.1 mg/kg/hr infusion postoperatively up to 24 hours) and oral memantine (5 mg BID \[first week\]; 10 mg BID \[following three weeks\]).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMDA active
Description: NMDA active group will involve ketamine (0.5 mg/kg IV bolus pre-incision and 0.1 mg/kg/hr infusion postoperatively up to 24 hours) and oral memantine (5 mg BID \[first week\]; 10 mg BID \[following three weeks\]).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroid active
Description: Steroid active group will involve two doses of dexamethasone; 25 mg given prior to starting surgery and 25 mg given on the morning of second postoperative day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroid active
Description: Steroid active group will involve two doses of dexamethasone; 25 mg given prior to starting surgery and 25 mg given on the morning of second postoperative day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NMDA placebo
Description: NMDA active group will involve normal saline (IV bolus pre-incision and infusion postoperatively up to 24 hours) and oral matching placebo to memantine (1 capsule BID \[first week\]; 1 capsule BID \[following three weeks\]).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMDA placebo
Description: NMDA active group will involve normal saline (IV bolus pre-incision and infusion postoperatively up to 24 hours) and oral matching placebo to memantine (1 capsule BID \[first week\]; 1 capsule BID \[following three weeks\]).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroid placebo
Description: Steroid placebo group will involve two doses of normal saline; one dose given prior to starting surgery and one dose given on the morning of second postoperative day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Steroid placebo
Description: Steroid placebo group will involve two doses of normal saline; one dose given prior to starting surgery and one dose given on the morning of second postoperative day.
Study: NCT03904797

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Young Children's Participation and Environment Measure (YC-PEM) electronic patient-reported outcome (e-PRO)
Description: Participants were primary caregivers (n=149) recruited from a large, urban early intervention program. All caregivers were approached by early intervention staff the month prior to the child's annual evaluation of progress.~Each caregiver confirmed his or her eligibility online by verifying that they were at least 18 years old; could read, write, and speak English or Spanish; had internet access; and had a child between 0-3 years old who had received early intervention for at least 3 months.~Participants enrolled online and provided consent, signed a HIPAA authorization for service record release, and then proceeded to completing a demographic questionnaire and YC-PEM e-PRO to receive an online report of their responses to share with their child's EI team.
Study: NCT02194153

Intervention type: DRUG
Intervention: Metalyse weight-adjusted
Study: NCT03731286

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Alpinia Galanga
Description: 2 capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Alpinia Galanga
Description: 2 capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Microcellulose crystalline
Description: 2 capsules
Study: NCT04587778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilot study II: Esketamine
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilot study II: Placebo
Description: intravenous infusion
Study: NCT02384174

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resistant starch

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary fibre (arabinogalactan, gum guar, pectin)
Study: NCT04329988

Intervention type: OTHER
Intervention: questionnaire
Description: A questionnaire will be made available to all eligible patients in general practitioners waiting rooms. This questionnaire will be composed by the single question, followed by the AUDIT and FACE questionnaires, and three socio-demographic questions. This questionnaire will be anonymous. Patients who agree to fill out a questionnaire will place it in a sealed box once completed.
Study: NCT04489264

Intervention type: DRUG
Intervention: Transplant, Autologous
Description: high dose chemotherapy followed by autologous stem cell transplantation
Study: NCT00934843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone (IVMP)
Description: Neonates with congenital heart disease requiring surgery utilizing a cardiopulmonary bypass (CPB)machine in the first month of life that receive ONE doses intravenous methylprednisolone (IVMP) prior to heart surgery.Compare the effects and preoperative and intraoperative IVMP (2 dose steroid)to intraoperative IVMP alone (single dose steroid) on the inflammatory response to CPB cardiopulmonary bypass.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone (two doses IVMP)
Description: Neonates with congenital heart disease requiring surgery utilizing a cardiopulmonary bypass (CPB)machine in the first month of life that receive TWO doses intravenous methylprednisolone (IVMP) prior to heart surgery.Compare the effects and preoperative and intraoperative IVMP to intraoperative IVMP alone on the inflammatory response to CPB cardiopulmonary bypass. The hypothesis is that neonates treated with preoperative IVMP as well as the standard intraoperative IVMP will have decreased production of pro-inflammatory cytokines.
Study: NCT03365843

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Montage bone putty
Description: Application of bone putty on cut sternal surfaces prior to application of conventional wires for closure of sternum during cardiac surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Sternal Closure
Description: Closure of sternum with standard wire cerclage.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Sternal Closure
Description: Closure of sternum with standard wire cerclage.
Study: NCT00680394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mifepristone
Description: 200 mg mifepristone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: misoprostol
Description: 800 buccal misoprostol + matching placebo or 1600 buccal misoprostol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: misoprostol
Description: 800 buccal misoprostol + matching placebo or 1600 buccal misoprostol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: 800 buccal misoprostol + matching placebo or 1600 buccal misoprostol
Study: NCT01800461

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OPC-Stroke
Description: Occupational therapy coaching intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Usual community care

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Usual community care
Study: NCT05705089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 MG
Description: Rivaroxaban 15 MG once daily orally + Dual anti-platelet therapy (clopidogrel (75 mg daily, orally)+aspirin (80 mg once daily, orally))

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Warfarin (to reach an INR goal of 2-2.5)+ Dual anti-platelet therapy (clopidogrel (75 mg daily, orally)+aspirin (80 mg once daily, orally))
Study: NCT04044326

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The Solero Microwave Ablation
Description: The Solero Microwave Ablation system (Angiodynamics Ltd, USA) with a single microwave applicator operating at a 2.45 GHz will be used to perform MWA
Study: NCT05445973

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Radiofrequency Ablation
Description: In brief, ablation was performed using a 200-W multichannel generator and a switching monopolar technique with separate clustered electrodes. Tumor targeting was done under the guidance of CEUS-CT/MRI FI, and the ablation procedure was monitored with US-FI. The ablation procedure was terminated when the operator expected to complete the ablation of the index tumor with a minimum 5-mm ablative margin on the US-FI images.
Study: NCT01722838

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: B-ME Intervention
Description: B-ME is a behavioral intervention of HIV prevention risk reduction administered in a group format during a 2.5 day retreat (19 hours) format.
Study: NCT00684190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3355
Description: 150 mg bid, oral, 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3355
Description: 150 mg bid, oral, 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 40 mg od, oral, 7 days
Study: NCT03705897

Intervention type: OTHER
Group type: OTHER
Intervention: Computerized Risk Stratification Tool
Description: Implement a novel computerized risk stratification tool in Parkland community-oriented primary-care clinics that collects data directly from patients and uses a computerized algorithm system to generate their personalized guideline-based next steps in the screening regimen

Intervention type: OTHER
Group type: OTHER
Intervention: Algorithmic Risk Stratification Tool
Description: Implement a novel algorithmic risk stratification system in Parkland's endoscopy clinics that, based on test findings entered by colonoscopists, generates personalized guideline-based next steps in the screening regimen for patients with colorectal polyps removed at olonoscopy

Intervention type: OTHER
Group type: OTHER
Intervention: Step completion assessment
Description: Assess completion of guideline-recommended steps in personalized screening regimens, under-screening, and over-screening
Study: NCT00684190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 40 mg od, oral, 7 days